Compare Equinix Inc (EQIX) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs Mesoblast Limited — how do they compare? Equinix Inc trades at $1,032.41 (market cap $102.95B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Equinix Inc is far larger — about 47.7× Mesoblast Limited's market cap, and Equinix Inc pays a 1.98% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| EQIX | MESO | |
|---|---|---|
Market Cap | $102.95B | $2.16B |
Sector | Real Estate | Technology |
52-Week High | $1.12K | $20.96 |
52-Week Low | $726.09 | $12.88 |
Enterprise Value | $124.08B | $2.17B |
Dividend Yield | 1.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,042.62, down 0.97% on the day, with strong analyst support (74.5% buy ratings) and a consensus price target of $1,120. The stock shows bullish technical signals with support at $1,040 and resistance at $1,067. Recent Q2 2026 earnings beat expectations with $4.83 EPS versus $4.73 expected, while revenue growth continues at 9.2B in 2025 with improving net margins to 15.63%. The company maintains robust cash flow from operations at $3.9B despite significant capital investments.
EQIX presents a compelling growth story driven by AI infrastructure demand and global digital expansion, though elevated valuation multiples (P/E 67.09) and substantial debt levels ($15.2B total debt) warrant caution. The stock offers dividend income with recent $5.16 payments, but investors should monitor execution risks in capital-intensive expansion and competitive pressures in the data center REIT sector.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
